Shares of Moderna jumped 5.22% to $97.61 at the session end on Friday, The Nasdaq Stock Market dropped 0.42% to $11855.
Moderna’s last close was $92.77, under its 52-week high of $103.2.
Moderna’s sales growth is 1216.8% for the current quarter and 2299% for the next. The company’s growth estimates for the ongoing quarter is a negative 67.6% and positive 142.9% for the next.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s stock is valued at $97.61 at 04:05 EST, under its 52-week high of $103.2 and way higher than its 52-week low of $17.68.
Moderna’s worth is way higher than its 50-day moving average of $75.37 and way higher than its 200-day moving average of $68.93.
According to Bloomberg Quint on Thu Nov 19, “Moderna Vaccine Production Is Gearing Up, Partner Lonza Says.”
According to Bloomberg Quint on Fri Nov 20, “EU Could Approve BioNTech, Moderna Vaccines in December.”